Nod to Covaxin trials on children

Tribune Web Desk

Updated At : 12:41 PM May 13, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, May 12

Bharat Biotech’s Covaxin has received the drug regulatory nod for advance clinical trials on children aged between 2 and 18 years.

The subject expert committee of the Central Drug Standards Control Organisation (CDSCO) said the trials would be conducted on 525 children at various sites, including at AIIMS-New Delhi, AIIMS-Patna and Meditrina Institute of Medical Sciences, Nagpur. — TNS

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles